NCI Definition: A rare but potentially life-threatening disorder characterized by the proliferation of histiocytes and macrophages and phagocytosis of red blood cells, white blood cells, and platelets. It may be inherited or secondary, due to infections, autoimmune disorders, or underlying malignancies. Signs and symptoms include fever, lymphadenopathy, hepatomegaly, splenomegaly, and pancytopenia. 
There is 1 clinical trial for hemophagocytic lymphohistiocytosis, of which 1 is open and 0 are completed or closed. Of the trial that contains hemophagocytic lymphohistiocytosis as an inclusion criterion, 1 is phase 2 (1 open).
Alemtuzumab, dexamethasone, and etoposide are the most common interventions in hemophagocytic lymphohistiocytosis clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.